Valuation: Damora Therapeutics, Inc.

Market Cap 1.84B 1.6B 1.49B 1.37B 2.58B 175B 2.61B 17.48B 6.86B 87.54B 6.91B 6.76B 291B P/E 2026 *
-15.7x
P/E 2027 * -14.4x
Enterprise Value 1.4B 1.21B 1.13B 1.04B 1.96B 133B 1.99B 13.28B 5.21B 66.46B 5.24B 5.13B 221B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.38%
Yield 2026 *
-
Yield 2027 * -
1 day-3.08%
1 week+2.29%
Current month+3.07%
1 month+0.27%
3 months+21.02%
6 months+18.29%
Current year+29.86%
1 week 28.42
Extreme 28.415
31.77
1 month 26.29
Extreme 26.29
34.89
Current year 16.5
Extreme 16.5001
34.89
1 year 2.45
Extreme 2.45
38.33
3 years 2.01
Extreme 2.01
77.25
5 years 2.01
Extreme 2.01
118.75
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 29/03/2026
Director of Finance/CFO - 30/04/2026
Chief Tech/Sci/R&D Officer 60 04/01/2026
Director TitleAgeSince
Chairman 40 22/03/2026
Director/Board Member 42 09/11/2025
Director/Board Member 41 09/11/2025
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell

General Counsel

-245 0.0004%
09/02/26
Fairmount Funds Management LLC
Fiscal yearCompany 8,713,000 14.4656%
09/02/26 Fiscal year

Director

129,000 0.2142%
Change 5-day change 1-year change 3-year change Capi.($)
-3.08%+2.29%+778.82%-55.57% 1.9B
+0.93%-0.63%+3.89%+14.93% 48.57B
+0.26%+2.93%+439.43%+533.80% 41.95B
-1.53%-2.25%+30.95%+7.15% 38.85B
+0.69%+2.40%+10.48%+63.05% 37.24B
+2.47%+2.63%+14.71%+48.37% 30.67B
-0.47%+1.16%+35.93%+126.09% 16.41B
+2.31%-0.49% - - 16.1B
+0.29%+1.87%+8.17%+18.60% 13.97B
-1.43%-2.63%+3.70%-36.38% 12.62B
Average +0.04%+1.15%+147.34%+80.00% 25.83B
Weighted average by Cap. +0.42%+0.29%+94.54%+119.71%

Financials

2026 *2027 *
Net sales - -
Net income -116M -101M -94.64M -86.57M -163M -11.09B -166M -1.11B -435M -5.54B -437M -428M -18.45B -145M -126M -118M -108M -204M -13.85B -207M -1.38B -543M -6.92B -546M -534M -23.04B
Net Debt -443M -384M -360M -329M -621M -42.18B -629M -4.21B -1.65B -21.07B -1.66B -1.63B -70.14B -326M -283M -265M -243M -458M -31.09B -464M -3.1B -1.22B -15.53B -1.23B -1.2B -51.71B
Logo Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells.
Employees
7
Date Price Change Volume
06/08/26 US$29.88 -3.08% 696,395
05/08/26 US$30.83 +2.70% 607,292
04/08/26 US$30.02 +5.11% 551,119
03/08/26 US$28.56 -1.48% 227,770
31/07/26 US$28.99 -0.75% 314,511
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
29.88USD
Average target price
44.67USD
Spread / Average Target
+49.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock